4 recruiting, 3 unknown, 2 withdrawn, 1 active not recruiting. 12 Phase 2, 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Recruiting 4, Unknown 3, Withdrawn 2, Active not recruiting 1, Completed 1, Not yet recruiting 1 |
| Phase 1 | 7 | Recruiting 2, Unknown 2, Withdrawn 2, Completed 1 |
Follow Relapsed Adult AML: new trials by email Literature Review of Relapsed Adult AML trials Research Report on Relapsed Adult AML
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Menin-Inhibitor Targeted Maintenance in AML Revumenib, Placebo - Relapsed Adult AML, Stem Cell Transplant Complications | Phase 2 | Not yet recruiting | Center for International Blood and Marrow Transplant Research | 146 | 2026-12-01 | 2026-06-22 |
| Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT AdaptNK, Fludarabine, Cyclophosphamide - Relapsed Adult AML, Refractory AML | Phase 1 / Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 18 | 2026-05-08 | 2026-05-19 |
| Tislelizumab with Azacitidine in the Treatment of R/R AML Aza, tislelizumab - Refractory AML, Relapsed Adult AML | Phase 1 / Phase 2 | Withdrawn | Institute of Hematology & Blood Diseases Hospital, China | 2024-10-05 | 2024-09-19 | |
| Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia AzaCITIDine Oral Tablet, Xospata - AML, Adult, Refractory AML | Phase 2 | Recruiting | French Innovative Leukemia Organisation | 33 | 2024-01-13 | 2025-03-24 |
| Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT Plerixafor - Relapsed Adult ALL, Relapsed Adult AML | Phase 2 | Unknown | The First Hospital of Jilin University | 28 | 2023-09-01 | 2023-11-21 |
| Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients Lintuzumab-Ac225, Venetoclax, Azacitidine - Acute Myeloid Leukemia, Relapsed Adult AML | Phase 1 / Phase 2 | Withdrawn | Actinium Pharmaceuticals | 2023-03-01 | 2023-07-20 | |
| Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML venetoclax combining chidamide and azacitidine (VCA) - Leukemia, Myeloid, Acute, Relapsed Adult AML | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 30 | 2022-01-12 | 2025-09-11 |
| New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia CAHAG regimen, Placebo regimen - Acute Myeloid Leukemia, Refractory Acute Leukemia | Phase 2 | Active not recruiting | The First Affiliated Hospital of Soochow University | 21 | 2021-09-01 | 2026-03-19 |
| Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX) Venetoclax Oral Tablet - Relapsed Adult AML, Refractory AML | Phase 1 / Phase 2 | Completed | Technische Universität Dresden | 55 | 2020-04-06 | 2026-09-02 |
| Venetoclax and Lintuzumab-Ac225 in AML Patients Lintuzumab-Ac225, Venetoclax, Spironolactone - Acute Myeloid Leukemia, Relapsed Adult AML | Phase 1 / Phase 2 | Unknown | Actinium Pharmaceuticals | 38 | 2020-01-15 | 2023-08-04 |
| Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia Tuspetinib, Venetoclax Oral Tablet, Azacitidine for Intravenous Infusion - Leukemia, Myeloid, Acute, Refractory AML | Phase 1 / Phase 2 | Recruiting | Aptose Biosciences Inc. | 240 | 2019-03-11 | 2025-08-26 |
| Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) GLIDE - Hematologic Cancer, Relapse Leukemia | Phase 1 / Phase 2 | Unknown | Ciusss de L'Est de l'Île de Montréal | 20 | 2017-02-06 | 2017-12-06 |
Leukemia, Myeloid, Acute (12) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Leukemia (1) · Leukemia, Myelomonocytic, Chronic (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1) · Recurrence (1)
Hematologic Diseases (12) · Hemic and Lymphatic Diseases (12) · Leukemia, Myeloid (12) · Neoplasms (12) · Neoplasms by Histologic Type (12) · Leukemia (11) · Bone Marrow Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Leukemia, Lymphoid (2) · Lymphatic Diseases (2) · Lymphoproliferative Disorders (2) · Blood Protein Disorders (1) · Cardiovascular Diseases (1) · Chronic Disease (1)
Azacitidine (4) · venetoclax (4) · Cyclophosphamide (1) · Infusions, Intravenous (1) · Interleukin-2 (1) · Spironolactone (1) · cc-486 (1) · fludarabine (1) · gilteritinib (1) · plerixafor (1) · revumenib (1) · tislelizumab (1)
Actinium Pharmaceuticals (2) · Aptose Biosciences Inc. (1) · Center for International Blood and Marrow Transplant Research (1) · Ciusss de L'Est de l'Île de Montréal (1) · French Innovative Leukemia Organisation (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Masonic Cancer Center, University of Minnesota (1) · Technische Universität Dresden (1) · The First Affiliated Hospital of Soochow University (1) · The First Affiliated Hospital of Xiamen University (1) · The First Hospital of Jilin University (1)
China (4) · United States (3) · Germany (2) · Australia (1) · Canada (1) · France (1) · New Zealand (1) · South Korea (1) · Spain (1)
Avinash Desai, MD (2) · Bing Xu (1) · Denis-Claude Roy, MD PhD (1) · Long Su, PhD (1) · Naval Daver, MD (1) · Silvy Lachance, MD (1) · Steven Devine, M.D (1)
PMID 33347715, PMID 39665627, PMID 41791831
2023 (1)